BMJ  2008;336:1447-1448 (28 June), doi:10.1136/bmj.39577.487558.BE (published 5 June 2008)

Editorials

Seroprotection against serogroup C meningococcal disease

Is higher if vaccination is given in the second decade of life rather than in the first

The first 150 words of the full text of this article appear below.

Neisseria meningitidis is a leading cause of bacterial meningitis worldwide. Most cases in developed countries are caused by endemic disease. The incidence is around 1-2 per 100 000,1 2 3 with rates among infants as high as 20 per 100 000.2 Children younger than 2 years have the highest incidence of meningococcal disease, with a second peak between 15 and 24 years. Most cases are caused by serogroups A, B, C, W-135, and Y. Serogroups C and B predominate in temperate countries.1 2 3

In the accompanying study, Snape and colleagues evaluate the persistence of serum bactericidal antibody against meningococcal serogroup C in a large cohort of adolescents originally immunised with serogroup C meningococcal conjugate vaccines at 6-15 years of age.4 These vaccines, now used in many countries, were licensed on the basis of immunogenicity rather than clinical efficacy.5 Despite the high public profile of meningococcal disease, it is relatively rare, which makes traditional . . . [Full text of this article]

Lucieni O Conterno, coordinator of infectious diseases discipline and clinical epidemiology unit1, Paul T Heath, reader in paediatric infectious diseases and honorary consultant2

1 Marilia Medical School, ZIP 17 519 030 Marilia, São Paulo, Brazil, 2 Child Health and Vaccine Institute, St George’s, University of London, London SW17 ORE

lucieni@famema.br


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to StumbleUpon StumbleUpon   Add to Technorati Technorati    What's this?

Relevant Articles

Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study
M D Snape, D F Kelly, S Lewis, C Banner, L Kibwana, C E Moore, L Diggle, T John, L M Yu, R Borrow, A Borkowski, C Nau, and A J Pollard
BMJ 2008 336: 1487-1491. [Abstract] [Full Text] [PDF]

Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis
Mary E Ramsay, Nick J Andrews, Caroline L Trotter, Edward B Kaczmarski, and Elizabeth Miller
BMJ 2003 326: 365-366. [Extract] [Full Text] [PDF]

Access jobs at BMJ Careers
Whats new online at Student BMJ